New Portable Fundus Imager from Volk
If you regularly visit patients in nursing homes, need to get a fundus image in the parking lot to follow your COVID-19 protocols or participate in screening events, Volk Optical says its new VistaView portable mydriatic retinal camera may be worth a look.
The VistaView integrates Volk’s high-resolution, all-glass, double aspheric optics with an intuitive digital platform to capture sharp, wide-field fundus images while managing patient data right on the device, the company says.
Volk says the VistaView is an all-in-one device that offers the widest field of view of any mydriatic fundus camera in its class at 55 degrees. The onboard app includes features such as image review, enhancement and analysis; and instant password protected report generation and transmission.
A voice capture option leaves both hands free to position the device for the best quality images, the company adds. The device has both autofocus and manual focus modes, as well as an illumination adjustment to help make photophobic patients more comfortable. Password protected reports and DICOM images are easily shared or exported for billing, consultation and referral, Volk says.
Apellis Announces Data from Phase Ib Study of Pegcetacoplan
Apellis Pharmaceuticals announced 18-month data from the Phase Ib APL2-103 study of pegcetacoplan (APL-2) in individuals with advanced geographic atrophy secondary to age-related macular degeneration and low vision. The study, which enrolled 12 patients with bilateral GA, assessed the safety of the Phase III formulation of pegcetacoplan (15 mg/0.1mL). Individuals were dosed monthly with pegcetacoplan in one eye using the fellow eye as an untreated control. In the current post hoc analysis, the growth rate of GA lesions in the treated eye was on average 52 percent (mean square root) slower than the opposite untreated eye (p=0.01). Of the 12 enrolled patients, no reported cases of inflammation were found, and one patient (8 percent) developed new-onset exudation at month 12. Read more.
Adverum to Present Data from the OPTIC Phase I Trial of ADVM-022
Adverum Biotechnologies will present additional clinical data for cohorts one to four in its OPTIC Phase I clinical trial of ADVM-022 intravitreal injection gene therapy in wet age-related macular degeneration during a live broadcast at the American Academy of Ophthalmology 2020’s virtual meeting. See the schedule of presentations.
Katena Acquires Micro-Select Instruments
Katena Products, a global provider of precision ophthalmic instruments, biologics and devices announced the purchase of Micro-Select Instruments. Micro-Select, located in St. Clair, Missouri, specializes in manufacturing high-precision ophthalmic instruments including forceps, needle holders and speculums. Read more.
Fighting Blindness to Host Free Webinar on Low-vision Resources
The Foundation Fighting Blindness is hosting a low-vision webinar to inform eye-care professionals about opportunities to enhance quality of life for their retinal disease patients. The organization says the interactive webinar is appropriate for all eye-care professionals, including retinal specialists, ophthalmologists, optometrists, rehabilitation professionals, occupational therapists, and orientation and mobility instructors. Register for the webinar.